- Conditions
- Long QT Syndrome
- Interventions
- Testosterone, Progesterone, Placebo, Ibutilide
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 65 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- EKG-QT Prolongation
- Interventions
- methadone, Hydromorphone
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Prolonged QT Interval
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Long QT Syndrome
- Interventions
- GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Congenital Disorders
- Interventions
- Epinephrine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Prolonged QTc Interval
- Interventions
- Deferiprone, deferiprone matching placebo tablets, moxifloxacin, placebo
- Drug
- Lead sponsor
- ApoPharma
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Long QT Syndrome, Abnormalities, Drug-Induced
- Interventions
- Progesterone, Ibutilide, Testosterone, Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana
- Conditions
- Long QT Syndrome, Abnormalities, Drug-Induced
- Interventions
- Progesterone, Ibutilide
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Long QT Syndrome
- Interventions
- GS-6615
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Prolonged QTc Interval, Pharmacokinetic
- Interventions
- 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Prolonged QT Interval in EKG and Sudden Death
- Interventions
- Progesterone, Placebo, Ibutilide
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Long QT Syndrome Type 3
- Interventions
- Eleclazine, Eleclazine placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • New York, New York • Rochester, New York
- Conditions
- Solid Tumors
- Interventions
- AZD6094 200 mg, Placebo, Moxifloxacin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Ondansetron
- Interventions
- Ondansetron
- Drug
- Lead sponsor
- C.R.Darnall Army Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Fort Hood, Texas • Tacoma, Washington